

Time Table
Day 1, July 27 (Thu)

			7	8	9	10	11	12	13	14	15	16	17	18	19		
Kobe International Exhibition Hall	Kobe International Conference Center (ICCK)	Room 1 (Portopia Hall)	South Building 1F		Opening Remarks	SY1 Countermeasures against side effects by immune check point inhibitors			President's Special Program How far have we eliminated disparities in cancer care?		JSMO 15th Anniversary Session Progress of Drug Therapy for Cancer						
		Room 2 (Convention Hall South)	Hall No.2 1F			ISY1 Latest status of EGFR-TKIs in EGFR mutant NSCLCs		MeS-1 Discussion, what are emerging issues in IO treatment?		EL1 Biomarker-driven clinical trial designs for targeted therapies	EL2 Systemic chemotherapy for metastatic gastric cancer	EL3 Current status and future perspective of chemotherapy for colorectal cancer	ISY2 Biomarker research and treatment strategy for metastatic colorectal cancer	ES-1 Better management of the later line treatment for mCRC -Roles of physicians and medical staff-			
		Room 3 (Convention Hall North)	Hall No.2 1F			WS1 About a good coping method with feeling of abandonment in patients and their families at transfer to palliative care unit (PCU) ~Can you transfer to PCU with relieved and trust?		MeS-2 New era of oncological treatment for metastatic colorectal cancer ~How to Translate Various Guidelines into Clinical Practice-		WS2 Decision making support for patients who are treating advanced cancer ~Would you like to do further cancer treatment, or not?~		SY2 Comprehensive Symptom Screening and Early Palliative care ~From the Start of Cancer Treatment					
		Room 4 (Hall A)	Hall No.1 2F			SY3 Investigator initiated trials for colorectal cancer in Japan		MeS-3 Metastatic Colorectal Cancer:From Disease Biology to Clinical Management		SY4 Update on Japanese reference genome and cancer genome sequence		JS6 Joint Symposium 6 (JCA/JSCO/JCS/JSMO) "Cancer Education" -Current Status and Challenges in the Year of Full-scale Start at Schools		ES-2 Safety of AVASTIN + Paclitaxel therapy for HER2-negative metastatic breast cancer in Japan			
		Room 5 (Hall B)	Hall No.1 2F			PD New developing treatment for advanced esophageal cancer		MeS-4 New Developments of Advanced Gastric Cancer Treatment		ISY3 Recent advances in the treatment of multiple myeloma		WS3 Update on Therapeutic approaches for advanced melanoma		ES-3 Rationale and clinical data for Immunology of head and neck cancer			
		Room 6 (Conference Room 2A)	Hall No.2 2F					MeS-5 Lenalidomide Based Treatment: New Treatment Concept of Transplant Ineligible Multiple Myeloma		JS1 Joint Symposium 1 (JASTRO/JSMO) Combination of Radiotherapy and New Anticancer Agents		WS4 Stereotactic Irradiation: Present situation and future indications		ES-4 Treatment strategy for Advanced squamous cell carcinoma of the lung			
		Room 7 (Conference Room 2B)	Hall No.2 2F					MeS-6 Recent Updates On Diagnosis and Treatment of Pancreatic and Gastrointestinal Neuroendocrine Tumors ~WHO2017: A new classification-						ES-5 Update of reactivation of hepatitis B virus			
		Room 8 (Conference Room 3A)	Hall No.2 3F			SY5 Overview and Future Prospect of "Promotion Plan for the Platform of Human Resource Development for Cancer"		MeS-7 Optimal Treatment Strategies for EGFR mutation-positive NSCLC		SY6 Present and Future of epigenome drug discovery against cancers		SY7 Treatment of bone metastasis: updated strategy		ES-6 Palliative Care for Patients with Advance/Metastatic Cancer			
		Room 9 (Conference Room 3B)	Hall No.2 3F			O1-1 Translational Research 1	O1-2 Translational Research 2	MeS-8 Treatment modality of soft tissue sarcoma and appropriate treatment with Pazopanib		O1-3 Basic Research	O1-4 Clinical Pharmacology	O1-5 Molecular Targeted Therapy		ES-7 Therapeutic Strategy of Genomic Biomarker Testing using Next-generation Sequencing in Lung Cancer Patients with Driver Gene Mutation			
Room 10 (Main Hall)	1F			EL4 Up to date information of novel drugs in hematologic malignancies in Japan	EL5 Academic Writing 101	EL6 Cancer care and treatment in community and the critical path for cancer	EL7 Genomic medicine	MeS-9 Strategic choices in the management of metastatic colorectal cancer	SL1 Histamine Hmethyltransferase as a potential therapeutic marker for the HER2+ breast cancer patients	EL8 Systemic therapy for genitourinary cancers	EL9 Clinical Practice Guideline and EBM Clinical Practice Guideline's Limitations	EL10 Communicating with Cancer Patients	WS5 Role of academia in anticancer drug discovery and development	ES-8 Why can't you give outpatient chemotherapy? ~Tips by four experts for administering outpatient chemotherapy beginning tomorrow~			
Room 11 (International Conference Room)	3F			WS6 New directions in the diagnosis and treatment of carcinoma of unknown primary		MeS-10 Save a patient's life from febrile neutropenia - Medical Team Challenge in Shikoku Cancer Center		ISY4 Guidelines of Molecular Targeted Therapies for Thyroid Cancer		ISY5 Immunotherapy for head and neck cancer: Future direction		ES-9 Reconsideration of treatment sequence in NSCLC without driver mutation					
Room 12 (Reception Hall)	3F			O1-6 Brain Tumor	O1-7 Head and Neck Cancer	MeS-11 Therapy of relapsed myeloma: an update		O1-8 Breast Cancer 1	O1-9 Breast Cancer 2	O1-10 Breast Cancer 3		ES-10 HER2-positive metastatic breast cancer: current and future treatment					
Room 13 (501)	5F			SY8 Current status and perspective of treatment for adolescent and young adults with cancer		MeS-12 Folfinrox in pancreatic cancer: Present and future		WS7 Future prospects of chemotherapy for biliary tract cancer		ISY6 Chemotherapy for advanced pancreatic cancer in a new era		ES-11 Essence of Cancer medicine: Communication Skills? or Arts?					
Room 14 (502)	5F			A brief overview of a revised edition of the Japanese guideline for the management of febrile neutropenia		MeS-13 Current standards and unsolved question in the treatment of sarcoma in advance phase		SY9 Multidisciplinary approach to soft tissue sarcoma: Current management		EL11 Sarcoma: Harnessing the Complexities of Cancer and Its Care	O1-11 Bone and Soft Tissue Tumors	ES-12 Applications of NGS in Precision Cancer Management					
Room 15 (504+505)	5F			O1-12 Neuroendocrine Tumors	O1-13 Hematological Malignancies 1 (Lymphoma)	MeS-14 What is the current and future Treatment Strategy against EGFR positive lung cancer		O1-14 Molecular / Genetic Diagnosis	O1-15 Hematological Malignancies 2 (MDS / Leukemia)	O1-16 Hematological Malignancies 3 (Myeloma / Lymphoma)		ES-13 Challenge and Initiative toward Precision Medicine for Cancer Patients through the Nationwide Cancer Genome Screening Project					
Patient Advocate Program (401+402)	4F			PAP 9:30-10:00	PAP 10:00-11:00	PAP 11:20-12:10		President's Special Program (Relay)		PAP 14:50-16:20							
Poster Area	Hall No.3 1F		8:00-9:00 Poster Set-up										9:00-18:00 Poster Display	18:00-19:00 Poster Session	19:00-19:30 Poster removal		
														Welcome Party at Poster Area 19:00~20:30			

Explanatory Notes

- JS =Joint Symposium
- ISY =International Symposium
- SY =Symposium
- WS =Workshop
- PD =Panel Discussion
- EL =Educational Lecture
- SL =Special Lecture
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral
- P =Poster

Simultaneous Interpretation (E&J)
 English Session
 Sponsored by Princess Takamatsu Cancer Research Fund